

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023.

Under the programme initiated 1 February 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023.

Since the announcement 13 March, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,570,171		2,526,273,159
13 March 2023	91,000	988.62	89,964,590
14 March 2023	90,000	985.20	88,667,601
15 March 2023	90,000	993.39	89,404,678
16 March 2023	92,000	980.18	90,176,584
17 March 2023	92,000	986.22	90,732,484
Accumulated under the programme	3,025,171		2,975,219,097

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 30,171,497 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 28 billion during a 12-month period beginning 1 February 2023. As of 17 March 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 3,025,171 B shares at an average share price of DKK 983.49 per B share equal to a transaction value of DKK 2,975,219,097.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#) and [YouTube](#).

Contact for further information

Media:

Ambre Brown Morley

+45 3079 9289

abmo@novonordisk.com

Natalia Salomao Abrahao (US)

+1 848 304 1027

niaa@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com